Zentiva Italia

What Zentiva Italia does

Zentiva Italia S.r.l. is the Italian operating subsidiary of Zentiva Group, a pan-European generic pharmaceutical company headquartered in Prague with Italian headquarters in Milan. The company develops, produces, and supplies generic medicines, branded drugs, value-added medicines, and biosimilars across six therapeutic areas: cardiology, metabolic diseases, oncology, respiratory, central nervous system, and consumer healthcare. Zentiva Italia distributes 620+ products through retail pharmacy and hospital channels, with a portfolio spanning generic prescription drugs (cetirizine, diclofenac, ibuprofen, paracetamol), self-medication products (ACIDITA' E REFLUSSO, GASTROSCHOUM REFLUSSO), and dietary supplements (D3 FORCE, GOODNIGHT, Serenil line). In 2025, the company expanded its consumer healthcare offering through the acquisition of five historic brands from Aboca (Propol2 EMF, Ruscoven, Serenil, Fisiodepur, Finocarbo) and signed a biosimilar license with Lupin.

The business model combines product sales across Italy with a broader B2B platform (Zent2U) offering API supply, contract manufacturing, and out-licensing of proprietary know-how, complemented by Prague Scientific's full-cycle development services. Zentiva Italia maintains ISO 9001:2015 and GDP certifications, and participates in pharmaceutical industry associations including Medicines for Europe. The subsidiary operates within a group that employs 5,400+ people across 30+ countries and serves 100+ million people across 40+ countries through four owned production sites and an external partner network. Corporate ownership transitioned in 2025, with Advent International announcing the sale of Zentiva to GTCR (expected to close early 2026), continuing the asset's trajectory under private equity sponsorship following its 2018 carve-out from Sanofi. Stefania Badavelli was appointed General Manager of Zentiva Italia in May 2025 to lead the next growth phase.

Name

Zentiva Italia

Legal name

Zentiva Italia S.r.l.

Website

https://zentiva.it

Company type

Private

Operating status

Operating

Short description

Zentiva Italia S.r.l., the Milan-based Italian subsidiary of pan-European generic pharmaceutical group Zentiva, develops, manufactures, and distributes 620+ generic, branded, biosimilar, and consumer healthcare products across cardiology, oncology, respiratory, metabolic, CNS, and OTC categories via retail pharmacy and hospital channels.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAIABAL

Generic Hospital & Institutional Products

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYCRADAGAE

Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity)

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Vitamins, Supplements & Sports Nutrition

SECONDARYCRADAGAD

Herbal & Botanical Supplements

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Vitamins, Supplements & Sports Nutrition

SECONDARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAE

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Consumer healthcare products
• OTC medications
• Branded pharmaceutical drugs

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals: Development, production and supply of high-quality generic medicines at accessible prices for retail and hospital channels
2. Branded Medicines: Brand drugs and value-added medicines including bioequivalent and advanced formulation products
3. Biosimilars: Biosimilar products developed in partnership for European markets
4. Consumer Healthcare: OTC products and supplements including recently acquired Aboca brands (Propol2 EMF, Ruscoven, Serenil, Fisiodepur, Finocarbo) for respiratory, circulatory system, and calm/sleep categories
5. Contract Manufacturing: B2B services through Zent2U platform including pharmaceutical ingredients (API), contract manufacturing, and out-licensing of proprietary know-how
6. Scientific Services: Full-cycle pharmaceutical development services through Prague Scientific including R&D, manufacturing, regulatory and pharmacovigilance support

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Zentiva Italia develops, produces, and supplies high-quality generic, branded, and biosimilar medicines across major therapeutic areas including cardiology, metabolic diseases, oncology, respiratory, CNS, and consumer healthcare. The portfolio spans generic prescription drugs, OTC self-medication products, and dietary supplements distributed through retail pharmacies and hospitals in Italy and across Europe.

Product overview

Zentiva Italia offers a diversified portfolio of pharmaceutical products including generic prescription drugs, self-medication (OTC) products, and dietary supplements. The portfolio covers major therapeutic areas: Cardiology, Metabolic Diseases, Oncology, Respiratory, Central Nervous System, and Consumer Healthcare. The product lineup includes self-medication products like ACIDITA' E REFLUSSO and GASTROSCHOUM REFLUSSO for gastrointestinal conditions; generic drugs such as CETIRIZINA ZENTIVA, DICLOFENAC ZENTIVA, IBUPROFENE ZENTIVA, and PARACETAMOLO ZENTIVA; and dietary supplements including D3 FORCE, D3 FORCE SPRAY, GOODNIGHT, PRONTO RECUPERO, and the Serenil product line. In 2025, Zentiva expanded its Consumer Healthcare portfolio by acquiring five historic brands from Aboca (Propol2 EMF, Ruscoven, Serenil, Fisiodepur, Finocarbo) to strengthen its presence in Respiratory, Circulatory System, and Calm & Sleep categories. The company also holds acquired brands Zerinol and Soluzione Schoum from 2022.

Differentiator

Problem solved

Functional benefit

Brands

• Zent2U: B2B platform offering pharmaceutical active ingredients (API), contract manufacturing solutions, and licensing of proprietary know-how
• Prague Scientific
• D3 FORCE
• GOODNIGHT
• ACIDITA' E REFLUSSO
• CETIRIZINA ZENTIVA
• DICLOFENAC ZENTIVA
• GASTROSCHOUM REFLUSSO
• IBUPROFENE ZENTIVA
• PARACETAMOLO ZENTIVA
• Propol2 EMF
• Ruscoven
• Serenil
• Fisiodepur
• Finocarbo

Products and services

• D3 FORCE
• D3 FORCE SPRAY
• GOODNIGHT
• ACIDITA' E REFLUSSO
• CETIRIZINA ZENTIVA
• DICLOFENAC ZENTIVA
• GASTROSCHOUM REFLUSSO
• IBUPROFENE ZENTIVA
• PARACETAMOLO ZENTIVA
• PRONTO RECUPERO
• Serenil Buonumore
• Serenil Calmansia
• Propol2 EMF
• Ruscoven (Plus Fluid, Plus Capsule, Biogel)
• Serenil
• Fisiodepur
• Finocarbo
• Zerinol
• Soluzione Schoum
• Zent2U B2B Services Platform
• Prague Scientific

Quantifiable outcome

• 100+ million people served across Europe
• +3 more outcomes

Named customers3 records

Segments8 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• AbocacoreStrategic or Co-development Partner · 30 June 2025Zentiva acquired five historic brands from Aboca (Propol2 EMF, Ruscoven, Serenil, Fisiodepur, Finocarbo) to expand access to natural Consumer Healthcare solutions across Europe. The acquisition strengthens Zentiva's position in respiratory, circulatory system, and calm/sleep categories, particularly in Italy, Spain, France, Portugal, Poland, Romania, and Greece.
• LupincoreStrategic or Co-development Partner · 1 January 2025Zentiva and Lupin signed a license and supply agreement for a TNF alpha inhibitor biosimilar, expanding biosimilar portfolio offerings in Europe.
• AdalvomajorStrategic or Co-development Partner · 1 January 2023Strategic partnership for respiratory, CNS, and dermatology therapeutic areas in Europe, expanding product portfolio and market reach.
• LILT Milano Monza BrianzamajorOthers · 1 January 2022Five-year charitable partnership supporting Milano Marathon to fund projects for oncology patients in economic-social vulnerability. LILT (Lega Italiana per la Lotta Contro i Tumori) promotes cancer prevention, rehabilitation, and healthcare.
• mAbxiencecoreStrategic or Co-development Partner · 1 January 2021Launch of first biosimilar in collaboration with mAbxience across 21 European countries, marking entry into biosimilar market.
• Medicines for EuropemajorOthersZentiva is a member of Medicines for Europe, which represents companies supplying most medicines in Europe. Active participation in executive team, board, and committees. Applies the Code of Conduct ensuring ethical marketing practices.
• BusinessEuropeminorOthersMembership in Advisory and Support Group participating in dialogues for competitive and sustainable European industrial policy with focus on medicine production and supply chain security.
• Fondazione Banco FarmaceuticomajorOthersCharitable partnership supporting annual Pharmaceutical Collection Days. For the fourth consecutive year, Zentiva supported the initiative to provide OTC medicines to people experiencing sanitary poverty in Italy.
• Zent2UcoreOthersB2B platform offering pharmaceutical ingredients (API), contract manufacturing, and out-licensing of proprietary know-how. Expertise in cardiology, urology, oncology, neurology, and hormonal treatments.
• Prague ScientificcoreOthersFull-cycle scientific and development services supporting pharmaceutical lifecycle from concept to compliant maintenance. Services span API and formulation R&D, production in Zentiva facilities, and scientific affairs including regulatory and pharmacovigilance.
• PARC (Pharmaceutical Applied Research Centre)minorStrategic or Co-development PartnerAcademic partnership for pharmaceutical innovation through collaboration with Prague Scientific.

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Lupin: Lupin is an Indian-headquartered global generic and biosimilar manufacturer. Zentiva signed a license and supply agreement with Lupin for a TNF-alpha inhibitor biosimilar in 2025, illustrating both partnership and direct generic competition across European markets.
• Krka: Krka is a Slovenian-headquartered generic pharmaceutical company with strong Central and Eastern European presence and a vertically integrated manufacturing footprint. It is a direct competitor to Zentiva in CEE markets and shares a similar focus on affordable retail generics and self-medication products.
• Polpharma: Polpharma is one of the largest Polish generic pharmaceutical manufacturers with significant CEE and Western European distribution. Comparable to Zentiva in vertically integrated generics, hospital and retail channel focus, and broad therapeutic area coverage.
• Stada Arzneimittel: Stada is a European-focused generic and consumer healthcare pharmaceutical company also backed by private equity (Cinven, Bain). It is highly comparable to Zentiva in business model, geographic focus, and dual retail/hospital channel mix, including branded OTC and generics across cardiology, CNS, and consumer health.
• Aurobindo Pharma: Aurobindo is an Indian-headquartered global generic pharmaceutical manufacturer with growing European presence. Zentiva's Ankleshwar facility and B2B platform (Zent2U) overlap with Aurobindo's API and finished dose strategy targeting Europe.

Broad incumbents

• Viatris: Viatris (formed from Mylan and Upjohn) is a global off-patent pharmaceutical company with significant European generic presence. It competes with Zentiva across retail generics, hospital injectables, and biosimilars, but at much larger scale and broader therapeutic breadth.
• Sandoz: Sandoz is the Novartis generics and biosimilars spin-off and a leading European generic player. It directly competes with Zentiva in retail generics and biosimilars, but operates at significantly larger scale with deeper proprietary biologics capabilities.
• Menarini Group: Menarini is a privately held Italian-headquartered pharmaceutical group with both branded specialty and consumer healthcare operations. While broader and more branded-specialty focused than Zentiva, it is a relevant Italian-market incumbent for retail pharmacy competition and OTC distribution channels.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with broad European presence across retail and hospital channels. Zentiva competes with Teva across most generic therapeutic areas in Italy and across Europe, but Teva operates at much greater scale with a more diversified specialty and biosimilar portfolio.

Emerging players

• Alvogen: Alvogen is a US-headquartered generic pharmaceutical company with European operations. Zentiva acquired Alvogen's Central and Eastern European business in 2019, but Alvogen remains a partial competitor in other European geographies and therapeutic segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@zentivaitalia
• Facebookfacebook.com/zentivaitalia
• LinkedInlinkedin.com/company/zentiva-italia
• Instagraminstagram.com/zentivait

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zentiva Italia